Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 19;13:2899–2909. doi: 10.2147/DDDT.S212500

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Luan and Chen.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Hypothetical model for CD20 binding of type I and type II CD20 antibodies explaining the impact of FcγRIIb on internalization. (A) Type I antibodies, such as rituximab, may bind to CD20 in a conformation that allows simultaneous binding to FcγRIIb and subsequent cross-linking and activation followed by internalization in lipid rafts. (B) Type II antibodies, such as obinutuzumab, may bind in a conformation that does not allow simultaneous binding to FcγRIIb, thus resulting in low/no internalization.